Paper Details

  1. Home
  2. Paper Details

Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

Author: BaldiniL, CortelezziA, FritzE, KührerI, LudwigH, PolliE, ScheithauerW

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 33 patients with multiple myeloma compared a combination of interferon-alpha-2C and VMCP chemotherapy with VMCP chemotherapy alone. The combination treatment resulted in a higher response rate and slightly longer survival, but a significant improvement in therapeutic gain was not achieved.
Paper Details　
Original Abstract of the Article :
Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-alpha-2C (rIFN-alpha-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2659740

データ提供：米国国立医学図書館（NLM）

Interferon-alpha-2C: A New Hope for Multiple Myeloma Treatment

Multiple myeloma is a complex and challenging cancer of plasma cells. This research investigates the potential of combining interferon-alpha-2C, a biologic response modifier, with conventional chemotherapy for treating multiple myeloma. The study randomly assigned 33 previously untreated patients to receive either interferon-alpha-2C plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP alone. The researchers monitored the patients' response to treatment, including response rates, duration of response, and overall survival.

Interferon-alpha-2C: A Promising Addition to Chemotherapy for Multiple Myeloma

The study observed a higher response rate and slightly longer duration of response in patients receiving interferon-alpha-2C plus VMCP compared to those receiving VMCP alone. While the study did not demonstrate a significant improvement in overall survival, it suggests that interferon-alpha-2C might enhance the effectiveness of conventional chemotherapy for multiple myeloma.

Multiple Myeloma: A Search for More Effective Therapies

This research highlights the ongoing search for more effective therapies for multiple myeloma. The study encourages further investigation into the potential role of biologic response modifiers, like interferon-alpha-2C, in combination with chemotherapy, potentially leading to improved outcomes for patients.

Dr.Camel's Conclusion

Confronting multiple myeloma is like traversing a scorching desert, where each step is a battle against relentless heat and exhaustion. This research explores a new approach, like discovering a refreshing oasis. Interferon-alpha-2C, a unique agent, might offer a way to strengthen our defenses against this challenging disease. While further exploration is needed, this study offers a hopeful glimpse of a more effective and compassionate journey through the treatment desert.

Date :
  1. Date Completed 1989-07-20
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

2659740

DOI: Digital Object Identifier

2659740

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.